|
 Korab Resources Limited - Float/IPO closing 16th August 2005
The federal government today took control of uranium mining in the Northern Territory setting the stage for a major shift in the Australia minerals sector. Under the new regime, uranium mining will no longer be banned in the NT and the approval process will be streamlined to allow for faster development of uranium properties.
Korab Resources, which owns uranium prospects in the NT is likely to benefit directly from this decision. The company controls 15 km of prime exploration ground stretching along strike from the Rum Jungle uranium mine, which was the first uranium mine in Australia operating from 1954 to 1971.
Andrej K Karpinski, Executive Chairman of Korab said in his company newsletter this morning that he believed "the recent developments are going to benefit the Company and the shareholders and that this event marks a major change in the environment in which we operate. In the last few hours the interest in Korab IPO has increased considerably and we have received several approaches from broking firms enquiring about the availability of stock. I would therefore recommend that you should lodge you subscription forms as soon as possible".
We agree with Andrej and encourage all our clients to get their applications in ASAP - any investors looking to make large investments above $20,000 are encouraged to give us a call on 1300 880 160 immediately to ensure we can get you the stock. Everyone else should be fine as long as they get their applications in soon.
Click here for more information and to download or request a prospectus.
Medical Therapies Limited - Float/IPO expected to close 15th August 2005
Medical Therapies is raising up to $10 million to help commercialise intellectual property from two Sydney universities for the potential treatment of cancer and arthritis.
The Intellectual Property (IP) acquired by Medical Therapies is derived from several significant discoveries made by researchers at the Universities of Sydney and Western Sydney. Together, these discoveries have the potential to generate a portfolio of chemotherapeutic and anti-inflammatory products to treat a range of diseases.
The company has significant potential and requires a closer look for investors looking to invest in a high return high-risk venture - click here for more information.
Regards
The InvestSMART Team
 |
Do you have managed funds that are not contributing to your TrailCapTM? Click here to learn more about TrailCapTM. |
|
